Kornimate/medical-research-clean huggingface dataset:
the relationship between sleep and glucose tolerance in prediabetes: the role of glp-1 in short sleepers

Conditions: Prediabetes

Summary: hypothesis 1. prediabetes patients who have insufficient sleep will have worse glucose tolerance than those with normal sleep duration. 2. prediabetes patients with short sleep will have a delayed or reduced glp-1 response to a standardized meal


Eligibility criteria:
inclusion criteria: 1. patients with prediabetes (hba1c 5.7-6.4% or history of fasting plasma glucose 100-125 mg/dl) who receive medical care at ramathibodi hospital 2. age 18 or older 3. can understand thai (speaking, listening and reading) 4. agree to participate by written informed consent exclusion criteria: 1. those who depend on others for feeding (such as stroke patients) 2. shift workers 3. history of congestive heart failure or low ejection fraction 4. chronic obstructive pulmonary disease, end stage renal disease or chronic liver disease (ast or alt \> 3 times the upper limit of normal) 5. use of medications: opioids/ narcotics , alpha blockers (prazosin, doxazosin, terazosin), clonidine, methyldopa, nitroglycerin 6. patients with permanent pacemaker 7. history of previous stroke

Keywords: prediabetes short sleepers glp-1
study to evaluate the treatment for chronic hepatitis c with normal transaminases in hiv positive patients

Conditions: Chronic Hepatitis C

Summary: in the current practice patients with normal levels of alt were not treated. however, a percentage of patients will present an advanced grade of fibrosis and cirrhosis. another reason to treat is the similar response to the treatment than elevated alt patients published recently in mono-infected patients. the investigators have not data concerning the evolution and response to the treatment in co-infected patients with normal alt. in the story of treatment chronic hepatitis c of co-infected patients hcv/hiv, sometimes, it assumes a behavior similar between mono and co-infected patients and the results are different. in the case of normal alt the investigators do not know if the natural history in co-infected patients is similar than the mono-infected patients, and also the response of the treatment. this study prospective and controls is the answer of this question. the main hypothesis is if the response of treatment in co-infected patients is not inferior than mono-infected patients. the objective is to evaluate the efficacy and safety of peginterferon alfa-2a and ribavirin in hiv positive patients with chronic hepatitis and persistently normal alt. every case (patient with normal alt) will have a control (patient with elevated alt), concerning genotype, gender and hospital.

the treatment of co-infected patients with normal alt would be very important because the evolution of cirrhosis in this patients is quicker and frequently than mono-infected patients.

Eligibility criteria:
inclusion criteria: * patients over 18 years old * hepatitis c co infected with stable hiv-1 and normal alt (case) or elevated levels of alt (control) * cd4 \> 200 cel/ml * stable anti-retroviral treatment for hiv during at least, the 6 previous months to the inclusion * negative contraception test * informed consent signed exclusion criteria: * pregnancy * any previous treatment for chc * any experimental treatment in the 6 previous weeks to the inclusion * cirrhosis grade b or c (child-pugh) * treatment with colony-stimulating factors, didanosine or zidovudine, immunomodulator therapy, isoniazid, rifampicin, ... * hepatic cancer * neutrophils \< 1500 cel/ml, platelets \< 70000 cel/ml, hemoglobin \< 11 g/dl (men) or \< 12 g/dl (women) previous to inclusion * severe psychiatric illness background * serum creatinin \> 1,5 times the upper normal limit * background of pulmonary or cardiovascular disease

Keywords: chronic hepatitis c normal alt hiv/hcv patients
neuropathy and anti-gfap antibodies

Conditions: Neurological Diseases or Conditions; Neurological Diseases Associated to Anti GFAP Antibodies

Summary: anti-glial fibrillary acidic protein (gfap) are antibodies associated to inflammatory diseases of the central nervous system. the gfap protein is highly expressed by astrocytes explaining these syndromes, but gfap is also expressed by immature and non-myelinating schwann cells. thus, these antibodies could also lead to damages of the peripheral nervous system (pns). moreover, such damages have already been reported on small studies, and there is a need for larger cohorts. the investigators will use the cohort of patients with neurological syndromes and anti-gfap antibodies identified in the cerebrospinal fluid (csf) of the "reference center for paraneoplastic neurological syndromes and autoimmune encephalitis" to determine the frequency of the pns involvement in these patients.


Eligibility criteria:
inclusion criteria: * - age \> 18 years old * neurological symptoms * anti-gfap antibodies identified in the csf exclusion criteria: * - uncomplete data in the medical records of patients

Keywords: gfap neuropathy
safety and efficacy study of inhaled pur003 on a controlled influenza virus challenge in healthy adult subjects

Conditions: Healthy

Summary: the objectives of the study are to demonstrate the effectiveness, safety and tolerability of multiple daily doses of inhaled pur003, in comparison with placebo, in healthy adults experimentally inoculated with influenza a/wisconsin/67/2005 (h3n2) virus.


Eligibility criteria:
inclusion criteria: * male and female subjects aged 18 to 45 years. * in general good health determined by a screening evaluation ≤120 days prior to double-blind imp administration and on the day of admittance to quarantine. * seronegative (nda) for challenge virus. * have not been vaccinated for influenza virus since 2006 (as determined in the medical history) or had a known influenza infection in the current season, defined as in the last 12 months. exclusion criteria: * presence or evidence of significant acute or chronic, uncontrolled medical or psychiatric illness. * abnormal pulmonary function as evidenced by clinically significant abnormality in spirometry. * health care workers (including doctors, nurses, medical students and allied healthcare professionals) anticipated to have patient contact within two weeks of discharge from quarantine. * intending to travel (to countries for which vaccinations are recommended or where high risk of infections exists). * presence of household member or close contact (until 14 days after discharge from quarantine) who is: less than 3 years of age; has any known immunodeficiency; is receiving immunosuppressant medications; is undergoing or soon to undergo cancer chemotherapy within 28 days of challenge. * subjects with diagnosed emphysema or chronic obstructive pulmonary disease (copd); elderly residing in a nursing home, affected by severe lung disease or medical condition; or a transplant (bone marrow or solid organ) organ recipient * subjects with any history of asthma, copd, pulmonary hypertension, reactive airway disease, or any chronic lung condition of any aetiology. * regular daily smokers during the 6 months prior to study entry or those who have a significant history of any tobacco use at any time (≥ total 10 pack year history = one pack a day for 10 years). * presence of any febrile illness or symptoms of upper or lower tract respiratory infection in the 28 days prior to viral inoculation (such subjects may be re-evaluated for enrolment after resolution of the illness). * receipt of any investigational drug within 3 months, or prior participation in a clinical trial of any influenza vaccine or medication within 1 year of participation.

Keywords: influenza healthy subject virus inoculation symptom scores viral shedding bioaerosol output
oxaloacetate in myasthenia gravis

Conditions: Myasthenia Gravis

Summary: this is a phase 1 clinical trial studying whether or not oxaloacetate has a positive effect on patients with myasthenia gravis. patients will be assigned to one of three cohorts which will determine the dose of oxaloacetate they will be given. subjects will take the study drug for 4 weeks and be on placebo for 4 weeks.


Eligibility criteria:
inclusion criteria: 1. patients 18 and older. 2. patients must have prior or current documentation of mgfa mg grades 2, 3, or 4a generalized mg, according to the mgfa classification system. these grades correspond to mild (2), moderate (3), and severe (4). 3. a total mg-adl score of greater than 3 at screening and baseline with no more than 50% of the total score being due to ocular symptoms. 4. patient's signs and symptoms should not be better explained by another disease process. 5. patients must be willing to complete the study and return for follow-up visits. 6. patients must be willing to give written informed consent before participating in this study. a copy of the signed consent must be kept in the patient's medical record. 7. patients can be on the following drugs as long as there has been no dose change for 60 days: azathioprine, cyclosporine, cyclophosphamide, mycophenolate mofetil, tacrolimus, methotrexate, ivig or other immunosuppressive drugs. 8. patients can be on prednisone as long as there has been no dose change for 30 days. 9. no planned changes in mg medications during the study exclusion criteria: 1. mgfa grade v within 6 months of screening. 2. a history of chronic degenerative, severe psychiatric, or neurologic disorder other than mg that can produce weakness or fatigue. 3. other major chronic or debilitating illnesses within six months prior to study entry. 4. female patients who are premenopausal and are: (a) pregnant on the basis of a serum pregnancy test, (b) breast-feeding, or (c) not using an effective method of double barrier (1 hormonal plus 1 barrier method or 2 simultaneous barrier methods) birth control (birth control pills, male condom, female condom, intrauterine device, norplant, tubal ligation, or other sterilization procedures). 5. thymectomy in the previous three months. 6. history of severe reactions to oaa 7. participation in a research study within the last 3 months
closure of muscular ventricular septal defects (vsds) with the amplatzer muscular vsd (muvsd) occluder - post approval study

Conditions: Ventricular Septal Defects

Summary: the amplatzer muscular vsd occluder was approved by the us food and drug administration (fda) in september, 2007. this study is designed to further evaluate the safety and effectiveness in subjects implanted with the amplatzer muscular vsd occluder.


Eligibility criteria:
inclusion criteria: 1. complex congenital muscular ventricular septal defects (vsd) of significant size to warrant closure. subjects must meet at least one of the following: 1. large volume left to right shunt (qp/qs \>2:1), 2. pulmonary hypertension (pa pressure \>50% systemic) and/or 3. clinical symptoms of congestive heart failure 4. banding of the pulmonary artery(ies) and in the opinion of the treating investigator closure of the vsd is clinically warranted. 2. subjects must meet at least one of the following criteria to be considered high risk for standard transatrial or transarterial surgical closure based on anatomical conditions: 1. left ventriculotomy or an extensive right ventriculotomy, 2. failed previous vsd closure, 3. multiple apical and/or anterior muscular vsds ("swiss cheese septum"), and/or 4. posterior apical vsds covered by trabeculae. 5. overall medical condition 3. subject/legally authorized representative has signed the informed consent 4. subject/legally authorized representative is willing to complete the follow-up requirements of this study exclusion criteria: 1. subjects with defects less than 4 mm distance from the semilunar (aortic and pulmonary) or atrioventricular valves (mitral and tricuspid) 2. subjects with severely increased pulmonary vascular resistance above 7 wood units and a right-to-left shunt and documented irreversible pulmonary vascular disease 3. subjects with perimembranous (close to the aortic valve) vsd 4. subjects with post-infarction vsd 5. subjects who weigh \< 5.2 kg 6. subjects with sepsis (local/generalized) 7. subjects with active bacterial infections 8. subjects with contraindications to anti-platelets

Keywords: muscular ventricular septal defects vsd
negative er expression assessed by 18f-fes pet/ct in the mbc with er-positive primary tumor

Conditions: Breast Cancer

Summary: to investigate the treatment pattern and efficacy of patients with positive primary er lesion but negative er expression in mbc using a novel convenient way of 18f-fluoroestradiol positron emission tomography/computed tomography (18f-fes pet/ct).


Eligibility criteria:
inclusion criteria: * patients diagnosed with breast cancer (according to international classification of diseases 10th revision) with confirmed metastasis, regardless of being de novo diagnosed or progressed from a non-metastatic stage. * mbc patients who underwent 18f-fes pet/ct at the fudan university shanghai cancer center between 2010 and 2022 * patients diagnosed with primary er-positive tumor and who were yet to receive any systemic therapy during the advanced stage exclusion criteria: * patients with incomplete medical records and those diagnosed with secondary primary tumors
elite sport and development of asthma

Conditions: Asthma

Summary: international studies have shown that elite athletes have a high prevalence of respiratory symptoms and asthma as compared to normal subjects. it is unclear whether the increased prevalence of asthma in elite athletes reflects "traditional asthma" or whether it is a special form of "sports asthma". the treatment of elite athletes with asthma seems to vary widely, and only a few studies have focused on the treatment of elite athletes with asthma. further knowledge of the pathogenesis of sports asthma would lead to a greater understanding and better treatment of the condition. this study will investigate the type of airway inflammation in elite athletes and examine the effect of treatment with inhaled steroids in combination with long-acting beta-agonists versus placebo in the same group.


Eligibility criteria:
inclusion criteria: * elite athletes * informed consent * doctor diagnosed asthma exclusion criteria: * current smoker or more than 10 pack-years * pregnancy, breast feeding or planning pregnancy during the study. * ics within the last 4 weeks prior to visit 1.

Keywords: sport asthma treatment airway inflammation
the effect of hcg treatment as a cardiovascular disease morbidity factor in sjogren syndrome patients

Conditions: Primary Sjogren Syndrome With Multisystem Involvement

Summary: sjogren syndrome is an autoimmune disease that mainly affects the salivary glands and lacrimal gland in addition to the effects of this disease is characterized by overall systemic muskals injury, pulmonary disease, peripheral neuropathy and vasculitis. in addition recent studies have shown that patients are at increased risk of the disease up to 2 cardiac events and stroke events hydroxychloroquine is an rheumatic disease process suppressants-antimalarials used to treat anti-inflammatory rheumatic diseases in many first-line treatment is sjogren syndrome. a recent study of the treatment in hydroxychloroquine effect on lipid profile sjogren syndrome patients showed a reduction in total cholesterol levels and increase in hdl. further studies of the impact made hydroxychloroquine systemic lupus patients erythematosus (sle) showed in atherosclerosis and morbidity and mortality reduction in cardiovascular. studies of patients with rheumatoid arthritis (ra) demonstrated reduced risk of developing diabetes and improved lipid profile research goals valuate the effect of hcq treatment in cardiovascular patients with primary sjogren syndrome

research goals valuate the effect of hcq treatment in cardiovascular patients with primary sjogren syndrome research methods the study will included patients that diagnosed with sjogren syndrome and was treated in meir medical center during the years 2003-2014 during the study will collect information on confounding factors , risk factors include cardiovascular acceptable such as diabetes, dyslipidemia, high blood pressure and the like, central nervous system involvement and steroid use study outcome will be one of the follow: 1. thrombosis of peripheral veins 2. arterial cardiovascular events 3. cardiac events (myocardial infarction 4. stroke (stroke and tia) 4. venous thrombosis events 5. pulmonary embolism in the study will be 500 patients inclusion criteria: 1. 18 years old 2. both sexes 3. patients that diagnosis in sjogren in treated in meir medical center in the years 2003-2014 and treated in hydroxychloroquine at least a month. exclusion criteria: 1. minors and special populations 2. patients that treated in hydroxychloroquine at less than a month. 3. patient that participate in clinical trial and treat with investigational product

Eligibility criteria:
inclusion criteria: 1. 18 years old 2. both sexes 3. patients that diagnosis in sjogren in treated in meir medical center in the years 2003-2014 and treated in hydroxychloroquine at least a month. exclusion criteria: 1. minors and special populations 2. patients that treated in hydroxychloroquine at less than a month. 3. patient that participate in clinical trial and treat with investigational product
efficacy and safety of hydrolysed red ginseng extract on dry eye

Conditions: Dry Eye

Summary: this study was conducted to investigate the effects of daily supplementation of hydrolysed red ginseng extract extract on dry eye.

this study was a 12 weeks, randomized, double-blind, placebo-controlled human trial. 46 subjects were randomly divided into hydrolysed red ginseng extract 10ml or placebo group. the investigators measured ocular surface disease index, tear break-up time, visual analog scale, schirmer's test, meibomian gland test and fluorescein staining.

Eligibility criteria:
inclusion criteria: * adult men and women over 19years * ocular surface disease index score is 13 scores and more at a screening * tear break-up time is 10 seconds less or those who have positive in ocular staining test at a screening * after fully hearing and fully understanding this clinical trials, those who agree to voluntarily decide to participate and to comply with the notice exclusion criteria: * those who have a body mass index(bmi) of less than 18.5 kg / m\^2 or greater than 35 kg / m\^2 at the screening * those who have clinically significant acute or chronic ophthalmologic, cardiovascular system, endocrine, immune, respiratory, liver biliary system, renal and urinary tract, neuropsychiatry, musculoskeletal, inflammatory and hematologic and gastrointestinal disorders * those who couldn't control diabetes at screening * those with acute eye infections or inflammation within 1 month before screening * those who have ophthalmic surgery within 3 months before screening * those who use contact lens 1 month before screening * those who take a medication or health function food that affects your promotion of dry eye within 1 month prior to the screening * those who have received antipsychotic medication within 3 months before screening * those who alcoholic or drug abuse suspected * those who participated in other clinical trials within 3 months before screening * laboratory test by showing the following results * aspartate transaminase(ast), alanine transaminase(alt) \> reference range 3 times upper limit * serum creatinine \> 2.0 mg/dl * pregnancy or breastfeeding * those who don't accept the implementation of appropriate contraception of a childbearing woman * principal investigator judged inappropriate for participation in the study because of laboratory test results, etc.
mbsr for pain catastrophizing in scd

Conditions: Anemia, Sickle Cell

Summary: significance: the purpose of this exploratory study is to test the feasibility, accessibility, and effects of a mindfulness-based stress reduction program (mbsr) on reducing pain catastrophizing in persons with sickle cell disease (scd) and chronic pain. one of the most difficult symptoms for scd patients to manage is chronic pain. approximately one-third of scd patients experience chronic pain, which is associated with pain catastrophizing. pain catastrophizing is a negative mental state toward pain stimuli and pain experience, and is associated with increased pain severity, pain interference, and lower social functioning, physical functioning, and mental health. there have been no psychobehavioral intervention studies that have attempted to alter the experience of pain catastrophizing in persons with scd. mbsr is a complementary group-based therapy that emphasizes nonjudgmental awareness of thoughts, feelings, and bodily sensations. with no pharmacological or non-pharmacological treatment for catastrophizing in persons with scd, mbsr offers a potential solution to this highly significant problem for both scd patients and providers. this project will be the first randomized controlled trial (rct) of mbsr to reduce pain catastrophizing, and improve quality of life for scd patients with chronic pain. methods: this study will enroll 60 adult patients with scd and chronic pain from the duke adult sickle cell clinic. patients will be randomized to a mbsr or wait-listed control group. the mbsr group will complete a 6- week, group-based telephonic mbsr program that is administered by a certified mbsr clinician once a week for 90 minutes. mbsr feasibility, acceptability, and effects on pain catastrophizing will be assessed by questionnaires at baseline, week 1, 3, and 6 in both groups. at the end of week 6, 10 randomly selected mbsr participants will complete semi-scripted telephone interviews to help assess intervention acceptability, and the wait-listed control condition will be offered the same mbsr intervention.


Eligibility criteria:
inclusion criteria: 1. provide written informed consent, 2. are \>age 21, 3. self-identify (to the pi at baseline assessment) that they are experiencing chronic, non-cancer pain that has persisted on most days for more than 6 months, and adversely affects their function or well-being, 4. are able to speak and read english, 5. have access to a telephone (or cell phone) in the home for the intervention and individual assessment interviews (data from the scd clinic indicate 82% of patients have a cell phone), 6. have access to a cd or mp3 player for homework assignments and daily practice, 7. are available during the scheduled telephone intervention, and 8. complete and return the baseline assessment exclusion criteria: * patients will be excluded if they report previously studying mbsr, currently receiving mindfulness-based or cognitive behavioral therapies, or being regular practitioners of mindfulness, including yoga.

Keywords: mindfulness mbsr scd experimental